Last updated: February 19, 2026
What Is the Drug Identified by NDC 43547-0330?
NDC 43547-0330 corresponds to Spravato (esketamine) nasal spray, approved by the FDA in March 2019. It is indicated for treatment-resistant depression (TRD) in conjunction with an oral antidepressant in adults.
Market Size and Demand Trends
Current Market Landscape
- Prevalence of Treatment-Resistant Depression (TRD): Estimated at 10-30% of major depressive disorder (MDD) patients globally, translating to approximately 8-12 million US adults.
- Market Adoption: Since approval, usage has increased, driven by clinicians seeking alternatives to traditional antidepressants for patients unresponsive to standard treatment.
- Competitors: Other fast-acting antidepressants or therapies, such as intranasal ketamine (off-label), intravenous ketamine, and emerging oral psychedelics (e.g., psilocybin).
Estimated Market Size (2023-2027)
| Year |
US Market Value (USD billions) |
Global Market Value (USD billions) |
| 2023 |
1.2 |
1.8 |
| 2024 |
1.6 |
2.4 |
| 2025 |
2.0 |
3.0 |
| 2026 |
2.5 |
3.8 |
| 2027 |
3.2 |
4.8 |
Sources: MarketResearch.com, IQVIA, MEDACorp estimates.
Drivers
- Increased recognition of TRD prevalence.
- Expanded insurance coverage for nasal esketamine.
- Growing acceptance among psychiatrists.
Challenges
- High treatment cost.
- Limited patient eligibility due to potential side effects.
- Competition from off-label ketamine and future oral formulations.
Pricing Dynamics
Current List Price
- Per dose: Approximately USD 590-620.
- Annual treatment (average 8-9 doses): Approx. USD 4,720-5,580.
Reimbursements and Insurance
- Pharmacies and clinics often face prior authorization hurdles.
- Insurers typically cover a significant share but may impose copayments.
- Some institutions offer patient assistance programs.
Competitive Pricing Trends
| Competitor |
Formulation |
Typical Price Range |
Approval Year |
| Spravato (esketamine) |
Nasal spray |
USD 590-620 per dose |
2019 |
| Off-label ketamine infusion |
IV |
USD 300-600 per session |
N/A |
| Oral psychedelics (emerging) |
Not yet approved |
Pending approval |
N/A |
Price Projections (2023-2027)
- Price stabilization: Remains around USD 600 per dose in the coming years.
- Potential discounts: Expected as competition intensifies and utilization increases, possibly reducing per-dose costs by 10-15% by 2026.
- New formulations: Oral esketamine or related drugs could drive price reductions due to ease of use and lower administration costs.
Regulatory and Policy Impact
- FDA: No significant pricing controls, but increased patterning of insurance coverage influences net reimbursement.
- CMS (Medicare/Medicaid): Reimbursement rates may influence overall pricing strategies.
- State and private insurers: Continued pressure for cost containment.
Market Entry Barriers and Opportunities
- Existing approvals limit new entrants but invite development of differentiated or oral formulations.
- Biosimilar or generic versions unlikely in the near term due to complex formulation and patent protections.
- Opportunities for companion diagnostics or personalized medicine approaches.
Key Takeaways
- NDC 43547-0330, Spravato (esketamine), commands a premium price, with list prices around USD 600 per dose.
- The US market size could reach USD 3.2 billion by 2027, driven by rising adoption.
- Price competition is limited; significant discounts unlikely without the emergence of oral or lower-cost alternatives.
- Insurance coverage and reimbursement policies significantly influence actual patient costs.
- Future revenue growth depends on expanding indications, increasing prescriber acceptance, and potential new formulations.
FAQs
Q1: Will the price of spravato decrease as more competitors enter the market?
A1: Likely, as off-label ketamine and oral alternatives gain ground, prompting price negotiations and discounts.
Q2: How does insurance coverage influence the effective price paid by patients?
A2: Insurance often covers most of the drug cost, reducing patient copays; however, high list prices may impact formulary decisions.
Q3: Are biosimilars or generics expected for esketamine?
A3: No, due to formulation complexity and patent protections, biosimilar or generic equivalents are unlikely in the near future.
Q4: What are the prospects for oral formulations impacting pricing?
A4: Oral formulations may reduce administration costs and improve access, leading to potential price reductions.
Q5: How might policy changes impact future pricing?
A5: Enhanced reimbursement policies or price caps could influence net prices, especially through negotiations with payers.
References
- Food and Drug Administration. (2019). FDA approves new nasal spray medication for treatment-resistant depression.
- IQVIA. (2023). US pharmaceutical market analysis.
- MarketResearch.com. (2023). Depression treatment market forecast.
- MEDACorp. (2022). Trends in antidepressant therapy pricing.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for novel depression therapies.
